四环医药宣布国家药监局受理其安纳拉唑钠用于反流性食管炎的新药上市申请

投资观察
Jul 06

四环医药控股集团有限公司宣布,其新药安纳拉唑钠用于治疗反流性食管炎的上市申请,已获中国国家药品监督管理局正式受理。

此次受理标志着该药物在中国商业化进程中的关键一步。反流性食管炎作为一种常见的消化系统疾病,其创新治疗药物的研发进展备受市场关注。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10